Imiquimod is a synthetic immune response modifier and active pharmaceutical ingredient used primarily in topical pharmaceutical formulations for the treatment of certain skin conditions. It belongs to the imidazoquinoline class of compounds and acts as an immune-modulating agent rather than a conventional cytotoxic drug.
Imiquimod has the molecular formula C14H16N4 and a molecular weight of 240.31 g/mol. Its CAS Number is 99011-02-6.
Imiquimod is a small-molecule immunomodulator developed for topical administration. It activates innate immune responses through stimulation of Toll-like receptor 7 (TLR7), leading to the production of cytokines and other immune mediators.
It is used in topical products for conditions including external genital and perianal warts, actinic keratosis, and certain superficial basal cell carcinomas, depending on the approved formulation and indication.
Imiquimod acts primarily as a TLR7 agonist. Activation of TLR7 stimulates innate immune signaling and promotes production of cytokines, including interferons and other inflammatory mediators.
This immune response contributes to the therapeutic effect against susceptible viral lesions and abnormal skin cells.
Imiquimod API is used in the development and manufacture of:
Imiquimod is manufactured through controlled chemical synthesis followed by purification, crystallization and drying. Pharmaceutical quality testing is performed to establish identity, assay, purity and other critical quality attributes.
Quality control may include identification, assay, related substances, water content, residue on ignition, elemental impurities and residual solvents according to the applicable approved specification.
Imiquimod is generally supplied as a white to off-white crystalline powder. It is practically insoluble in water and has limited solubility in many conventional solvents.
Imiquimod should be stored in a tightly closed container under controlled conditions and protected from excessive moisture, heat and direct light. Storage conditions should follow the manufacturer's current CoA, SDS and validated stability requirements.
Depending on the intended pharmaceutical application, documentation may include:
Imiquimod is an important synthetic immune response modifier used primarily in topical dermatological products. Its selective activation of TLR7-mediated immune signaling makes it a valuable API for pharmaceutical formulations targeting specific viral and precancerous or superficial skin lesions.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | Approximately 300°C (decomposition) |